Cytosorbents Corp (NASDAQ:CTSO)
| Market Cap | $13.11M-74.9% |
| Revenue (ttm) | $37.46M+1.3% |
| Net Income | -$16.88M-59.4% |
| EPS | -$5.33-43.7% |
| Shares Out | 3.15M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,692 |
| Open | $4.52 |
| Previous Close | $5.13 |
| Day's Range | $4.16 - $4.79 |
| 52-Week Range | $2.84 - $17.00 |
| Beta | 1.48 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | Mar 24, 2027 |
About CTSO
Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.
Cytosorbents Corp Stock Analysis — InsiderScore
Cytosorbents Corp scored higher than 78% of companies evaluated by InsiderBuying, and ranked 10th out of 52 stocks in the healthcare sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Cytosorbents Corp bought $120.4K of stock across 7 purchases in the last 90 days, the largest of them $70.0K.
The average purchase added about 7% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 24, 2027Earnings report
$CTSO stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CTSO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CTSO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CTSO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CTSO Revenue by Segment or Geography
| SEGMENT INFORMATION | $9.73M | 99.93% |
| (Gain) loss on foreign currency transactions | $7.00K | 0.07% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CTSO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CTSO from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CTSO
| VTIVanguard Morningstar Total Stock Market ETF | $227.95K |
| VXFVanguard Extended Market ETF | $130.40K |
| PQSGPGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Growth ETF | $20.66K |
| MSSMMorgan Stanley Pathway Funds - Small-Mid Cap Equity ETF | $4.29K |
| STSBiShares Factors US Small Blend Style ETF | $1.23K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from CTSO’s recent data — informational, not investment advice
What’s Behind the Score
News check: Operating cash flow breakeven achieved in Q3 with positive financing activity and regulatory progress; concrete operational milestone outweighs modest capital raise.
Recent Insider Activity
Insider Score Trend Over Time
+35.6 since Sep 24Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| PQSG | PGIM ETF Trust - PGIM QMA Strategic Alpha Small-Cap Growth ETF | 0.16% |
Weight is the stock’s share of each fund’s holdings.
